Patents involving monoamine oxidase (MAO): a comprehensive update (2022–2025) on its inhibitors and applications
Recently patented MAO inhibitors show notable properties, including significant isoform selectivity and therapeutic potential toward other diseases, such as fibromyalgia, CDKL5-deficient disorder, neuropathic pain, and Alzheimer's disease.
Authors
- Francesca Diomede (ORCID: https://orcid.org/0000-0002-0384-6509)
- Paolo Guglielmi (ORCID: https://orcid.org/0000-0001-5701-6925)
- Ilaria D’Agostino
- Moataz A. Shaldam
- Marwa Balaha
- Haytham O. Tawfik
- Simone Carradori
Institutions
- University of Pisa (IT)
- Kafrelsheikh University (EG)
- Tanta University (EG)
- University of Chieti-Pescara (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Expert Opinion on Therapeutic Patents
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1080/13543776.2026.2633345
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00